U.S. Stock Market Midday Update

Instil Bio rose by 11.10%, with increased trading volume. Based on recent important news:

1. On June 23, Standard BioTools sold its Somalogic division to Illumina, driving the biotechnology sector up, benefiting Instil Bio with a stock price increase of 11.10%.

2. On June 12, China National Pharmaceutical announced a significant external licensing deal, boosting market confidence in the biotechnology industry, indirectly affecting Instil Bio's stock price.

3. On June 9, Guangkang Biochemical saw a surge in block trading, making the biotechnology sector overall active, benefiting Instil Bio's stock price.

Stocks with High Trading Volume in the Industry

ProKidney rose by 31.10%, with increased trading volume. Based on recent important news:

1. On July 8, ProKidney announced significant results from the REGEN-007 trial, with an eGFR slope improvement of 78% and no serious adverse events, leading to a 31.10% stock price increase.

2. On July 8, the company stated that the results of the REGEN-007 trial enhanced confidence in the PROACT 1 trial design, with expectations for FDA accelerated approval.

3. On July 9, management announced participation in an important conference, further driving the stock price up.

Calidi Biotherapeutics rose by 297.01%. Based on recent key news:

1. On July 8, Calidi Biotherapeutics published an editorial on NetworkNewsWire, increasing market attention on the company and significantly boosting the stock price.

2. On July 8, Calidi Biotherapeutics announced its position in the Dynamic Brand Portfolio, further enhancing investor confidence, leading to a stock price surge.

3. On July 9, positive market sentiment towards Calidi Biotherapeutics continued, with trading volume reaching $347 million, setting a new 60-day high.

Abbvie rose by 0.03%, with increased trading volume. Based on recent important news:

1. On July 9, analysts rated Abbvie as a moderate buy, but it was not included in the recommended list, affecting market confidence and causing stock price fluctuations.

2. On July 9, the innovative drug industry experienced significant volatility, with institutions increasing their holdings in innovative drug assets, driving the stock price up.

3. On July 7, progress in CAR-T cell therapy in the field of autoimmune diseases increased market attention on related treatments, impacting the stock price.

Stocks with High Market Capitalization in the Industry

Abbvie rose by 0.03%, with a market capitalization of $335.1 billion. Based on recent important news:

1. On July 9th, analysts believe Abbvie is not on the recommended list, despite its rating being moderate buy, leading to insufficient market confidence and stock price fluctuations.

2. On July 9th, the learning barriers and market biases in the innovative drug industry affected investor sentiment, resulting in stock price fluctuations.

3. On July 9th, the potential of CAR-T cell therapy in autoimmune diseases was widely discussed, which may influence market expectations